Fourteen months after the FDA rejected the new antipsychotic cariprazine, the developers say they have gathered together a new batch of late-stage data to demonstrate its effectiveness for schizophrenia, but the statement has done little to dispel the lingering doubts about this one-time blockbuster hopeful.

…read more

Source: Actavis, Richter tout new PhIII data for their tarnished schizophrenia drug


0 No comments